Distribution of CD4+ and CD8+ exhausted tumor-infiltrating lymphocytes in molecular subtypes of Chinese breast cancer patients

被引:8
|
作者
Shi, Feng [1 ]
Chang, Hong [1 ]
Zhou, Quan [1 ]
Zhao, Yan-Jie [2 ]
Wu, Guang-Jiang [3 ]
Song, Qing-Kun [4 ,5 ]
机构
[1] Capital Med Univ, Beijing Shijitan Hosp, Dept Pathol, Tieyi Rd 10, Beijing 100038, Peoples R China
[2] Capital Med Univ, Beijing Shijitan Hosp, Dept Med Oncol, Beijing 100038, Peoples R China
[3] Capital Med Univ, Beijing Shijitan Hosp, Dept Infect Control, Beijing 100038, Peoples R China
[4] Capital Med Univ, Beijing Shijitan Hosp, Dept Sci & Technol, Tieyi Rd 10, Beijing 100038, Peoples R China
[5] Dept Canc Epidemiol, Beijing Key Lab Canc Therapeut Vaccine, Beijing 100038, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2018年 / 11卷
关键词
breast cancer; tumor-infiltrating lymphocyte; PD-1; molecular subtype; POOR-PROGNOSIS; TRIAL; CHEMOTHERAPY; SURVIVAL; PD-L1; TRASTUZUMAB; MULTICENTER; EXPRESSION;
D O I
10.2147/OTT.S168057
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Purpose: Breast cancer (BC) is the leading cancer affecting Chinese women; however, the immune microenvironment between molecular subtypes is less reported. This study aimed to investigate the distribution of tumor-infiltrating lymphocyte (TIL) subpopulations, especially exhausted CD4(+) and CD8(+). TILs in Chinese BC patients. Patients and methods: A total of 133 patients with breast invasive ductal carcinoma were recruited consecutively from January 1, 2012 to December 31, 2013, and TILs were detected in H&E-stained sections. Expression profiling of PD-1, CD4 and CD8 was determined by immunohistochemistry on 4 mu m formalin-fixed paraffin-embedded tissue sections. The distribution of TILs was analyzed based on hormone receptor status and molecular subtypes. Results: PD-1(+), CD4(+) and CD8(+). TI Ls distributed differently based on molecular subtypes. Compared to Lumina! A, triple-negative breast cancer (TNBC) patients had more PD-1(+) TILs (39/high-power field [HPF] vs 11/HPF), PD-1(+ )helper T (CD4(+)) cells (28/HPF vs 10/HPF), and PD-1(+). cytotoxic (CD8(+)) T-cells (3/HPF vs 2/HPF). Conclusion: TILs are distributed differently based on molecular subtypes. TNBC patients exhibit more PD-1(+). exhausted TILs, representing an inhibitory immune microenvironment. PD-1/PD-L1 pathway is a potential therapeutic target of TNBC.
引用
收藏
页码:6139 / 6145
页数:7
相关论文
共 50 条
  • [41] Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis
    Steele, Keith E.
    Tan, Tze Heng
    Korn, Rene
    Dacosta, Karma
    Brown, Charles
    Kuziora, Michael
    Zimmermann, Johannes
    Laffin, Brian
    Widmaier, Moritz
    Rognoni, Lorenz
    Cardenes, Ruben
    Schneider, Katrin
    Boutrin, Anmarie
    Martin, Philip
    Zha, Jiping
    Wiestler, Tobias
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [42] Predictive and prognostic significance of CD8+ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy
    Al-Saleh, Khalid
    Abd El-Aziz, Nashwa
    Ali, Arwa
    Abozeed, Waleed
    Abd El-Warith, Ahmed
    Ibraheem, Ahmed
    Ansari, Jawaher
    Al-Rikabi, Ammar
    Husain, Sufia
    Nabholtz, Jean-Marc
    [J]. ONCOLOGY LETTERS, 2017, 14 (01) : 337 - 344
  • [43] Enhanced expression of IFN-γ mRNA in CD4+ or CD8+ tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer
    Elsässer-Beile, U
    Rindsfüser, M
    Grussenmeyer, T
    Schultze-Seemann, W
    Wetterauer, U
    [J]. BRITISH JOURNAL OF CANCER, 2000, 83 (05) : 637 - 641
  • [44] Enhanced expression of IFN-γ mRNA in CD4+ or CD8+ tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer
    U Elsässer-Beile
    M Rindsfüser
    T Grussenmeyer
    W Schultze-Seemann
    U Wetterauer
    [J]. British Journal of Cancer, 2000, 83 : 637 - 641
  • [45] Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights
    Kumar, Sandeep
    Singh, Sunil Kumar
    Rana, Basabi
    Rana, Ajay
    [J]. DRUG DISCOVERY TODAY, 2021, 26 (04) : 951 - 967
  • [46] CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes
    Parodi, Alessia
    Battaglia, Florinda
    Kalli, Francesca
    Ferrera, Francesca
    Conteduca, Giuseppina
    Tardito, Samuele
    Stringara, Silvia
    Ivaldi, Federico
    Negrini, Simone
    Borgonovo, Giacomo
    Simonato, Alchiede
    Traverso, Paolo
    Carmignani, Giorgio
    Fenoglio, Daniela
    Filaci, Gilberto
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (05) : 851 - 862
  • [47] CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes
    Alessia Parodi
    Florinda Battaglia
    Francesca Kalli
    Francesca Ferrera
    Giuseppina Conteduca
    Samuele Tardito
    Silvia Stringara
    Federico Ivaldi
    Simone Negrini
    Giacomo Borgonovo
    Alchiede Simonato
    Paolo Traverso
    Giorgio Carmignani
    Daniela Fenoglio
    Gilberto Filaci
    [J]. Cancer Immunology, Immunotherapy, 2013, 62 : 851 - 862
  • [48] Prognostic implication of CD8-positive tumor-infiltrating lymphocytes of rectal cancer
    Koizumi, K
    Shinto, E
    Ueno, H
    Hashiguchi, Y
    Matsubara, O
    Mochizuki, H
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S108 - S108
  • [49] Impact of Tumor-Infiltrating Lymphocytes in Breast Cancer Patients with Neoadjuvant Chemotherapy Depends on Subtypes
    Matsumoto, Akiko
    Jinno, Hiromitsu
    Ishida, Hiroki
    Hiraiwa, Kunihiko
    Nakamura, Tetsuya
    Ueyama, Yoshihito
    Saito, Junichi
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [50] CD8+ tumor infiltrating lymphocytes strongly correlate with molecular subtype and clinico-pathological characteristics in breast cancer patients from Sudan
    Mahmoud Mohamed
    Hina Sarwath
    Nada Salih
    Devendra Bansal
    Prem Chandra
    Nazik E. Husain
    Lotfi Chouchane
    Ali A. Sultan
    Shahinaz Bedri
    [J]. Translational Medicine Communications, 1 (1)